Pulse Biosciences Inc. shares reached an all‑time high of $56.15, trading just below the 52‑week peak of $55.37. The market value of the company stood at about $3.92 billion. Over the past year the stock advanced roughly 264%, while the year‑to‑date gain was about 255%.
In the second quarter, Pulse reported an adjusted loss of $0.36 per share, missing Wall Street’s expectation of a $0.28 loss. Revenue for the quarter was $400,000, below the $600,000 consensus forecast.
Analyst activity intensified following the price move. Freedom Capital initiated coverage with a buy rating and set a price target of $73, citing the company’s nanosecond pulsed field ablation (nsPFA) technology for atrial fibrillation. Needham also began coverage, assigning a buy rating and a $58 target, highlighting the next‑generation pulse field ablation platform. Canaccord raised its target from $32 to $43 while maintaining a buy stance, pointing to clinical and regulatory progress in the company’s ablation system.
Investor sentiment was further buoyed by faster enrollment in the pivotal atrial fibrillation trial and progress in thyroid and surgical program pipelines. An InvestingPro note flagged the stock as trading near its 52‑week high, while its fair‑value model suggested the current level may be overvalued.
The company’s shares have attracted additional analyst commentary, with 16 ProTips and a detailed Pro Research Report available on InvestingPro for subscribers.
